Seeking Alpha
16 Nov 2026, 05:24 UTC · 20h ago
DiaMedica Therapeutics: Maintaining "Buy" DM199 FGR Data November 2026 And AIS Advancement
Impact · against what's priced in
The primary catalyst for DMAC is the upcoming FGR data update on November 24, 2026, which represents new information regarding the program's viability. Other updates regarding the ReMEDy2 stroke trial and U.S. preeclampsia initiation are already factored into the current valuation.
- DMAC+0.60
No priced-in read yet





